MedTrace Logo

DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic Cancer

NCT02079363 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 330

Last updated 2014-07-30

No results posted yet for this study

Summary

The objectives of this project are to test whether alteration in DNA hypermethylation in plasma is:

* a diagnostic marker for pancreatic cancer
* a prognostic marker for pancreatic cancer
* a marker for recurrence of pancreatic cancer
* changing during the course of chronic pancreatitis, with the purpose of finding patients with high risk of developing pancreatic cancer

Conditions

Interventions

OTHER

No interventions, this is an observational study

Sponsors & Collaborators

  • Aalborg University Hospital

    lead OTHER

Principal Investigators

  • Stine Dam Henriksen, MD · Department of Gastrointestinal Surgery, Aalborg University Hospital, Denmark

  • Ole Thorlacius-Ussing, MD,DMSc,Prof · Department of Gastrointestinal Surgery, Aalborg University Hospital, Denmark

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2017-08-31
Completion
2018-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02079363 on ClinicalTrials.gov